EGFR and cancer: Using MuSyC analysis (35), we found that synergy could occur with respect to maximal efficacy, potency, and/or cooperativity for the combination of an anti-CD47 antibody with EGFR TKIs, lorlatinib, or sotorasib when used with their respective cancers (Supplemental Figure 11 and Supplemental Table 1).